Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, Y and W-135 conjugate vaccine (CanSino Biologics Inc.)
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Menhycia (Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine [CRM197]) is a quadrivalent vaccine developed by CanSino Biologics for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The vaccine utilizes the CRM197 carrier protein, a non-toxic mutant of diphtheria toxin, to which the capsular polysaccharides of the four serogroups are individually conjugated. This conjugation process enhances the immune response by engaging T-cell-dependent pathways, which is particularly critical for providing long-lasting immunity in infants and young children. While already approved in China for use in children aged 3 months to 3 years, CanSino is currently pursuing an indication expansion for individuals aged 7 to 59 years, which is in Phase 2 clinical development.
- Brand names
- Menhycia曼海欣
- Other names
- Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)MCV4-CRM197MCV-4-CRM197MCV 4-CRM197Quadrivalent Meningococcal Conjugate Vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, Y and W-135 conjugate vaccine (CanSino Biologics Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, Y and W-135 conjugate vaccine (CanSino Biologics Inc.).